Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain

Back

ESC Professional Premium Access

Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain

Session: Biotherapies in cardiovascular disease: from bench to bedside

Topic: Anticoagulants

Speaker: Doctor A. Kithcart (US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Aaron Kithcart

(United States of America)

0 follower

5 more presentations in this session

CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis

Speaker: Professor M. Holinstat (Ann Arbor, US)

RKER-012, a novel modified ActRIIB ligand trap, attenuated right ventricular cardiomyopathy in a preclinical model of pulmonary arterial hypertension.

Speaker: Doctor P. Jain (Lexington, US) Doctor K. Babbs (US)

First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects

Speaker: Doctor A. Gabrielsen (Gothenburg, SE)

Phase I results of both IV and oral administration for CG-0255: a novel fast-acting antiplatelet drug with a new activation pathway

Speaker: Doctor X. Chen (Shanghai, CN)

Developing p21-activated kinase 1 (PAK1) activators to treat hypertrophic cardiomyopathy (HCM)

Speaker: Miss Y. He (Oxford, GB)

Access the full session

Biotherapies in cardiovascular disease: from bench to bedside

Speakers: Doctor A. Kithcart, Professor M. Holinstat, Doctor P. Jain, Doctor K. Babbs, Doctor A. Gabrielsen...

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources